Back to top

Image: Bigstock

Medpace (MEDP) Down 3.1% Since Last Earnings Report: Can It Rebound?

Read MoreHide Full Article

A month has gone by since the last earnings report for Medpace (MEDP - Free Report) . Shares have lost about 3.1% in that time frame, outperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Medpace due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Medpace Holdings, Inc. before we dive into how investors and analysts have reacted as of late.

MEDP Q3 Earnings and Revenues Surpass Estimates

Medpace Holdings, Inc. reported third-quarter 2026 earnings per share of $4.84, up 25.4% year over year. The figure surpassed the consensus estimate by 8.76%.

Revenues totaled $716 million, increasing 8.5% year over year (up 8.6% on a constant currency basis) and beating the consensus estimate by 1.02%.

MEDP's New Business Awards and Backlog Trends

Net new business awards totaled $873.4 million, rising 10.6% from the prior-year quarter. Awards over the trailing 12 months reached $3.02 billion, increasing 23.9% year over year.

Ending backlog stood at $3.17 billion, up 5.6% year over year. The backlog conversion rate improved to 23.8% from 23% in the year-ago quarter. Approximately $1.99 billion of backlog is expected to convert into revenues over the next 12 months.

Medpace's Revenue Composition and Client Trends

The company continued to witness healthy demand across its core therapeutic areas, particularly oncology. Management noted that new business awards shifted toward traditional oncology projects, while metabolic-related awards moderated. However, the pipeline of potential metabolic projects remained strong.

Metabolic diseases accounted for 32% of trailing 12-month revenues, followed by oncology at 30%. Small biopharmaceutical customers contributed 83% of revenues. The top five and top 10 customers accounted for approximately 31% and 39%, respectively, of trailing 12-month revenues.

MEDP's Operating Costs and Margin Performance

Total direct costs in the third quarter increased 6.3% year over year to $492.1 million. Direct service costs, excluding depreciation and amortization, rose 9.9% to $204.9 million. Reimbursed out-of-pocket expenses increased 3.8% to $287.3 million. Selling, general and administrative expenses climbed 7.7% to $51.8 million.

EBITDA increased 16% year over year to $172.1 million, while the corresponding margin expanded 150 bps to 24%. The improvement primarily reflected a lower proportion of reimbursed out-of-pocket expenses.

Medpace's Liquidity and Shareholder Returns

Medpace exited the third quarter with cash and cash equivalents of $705.3 million, compared with $497 million at the end of 2025.

Cumulative operating cash flow as of September 2026 was $530.4 million, compared with $520.6 million in the year-ago period. Free cash flow amounted to $196.4 million, compared with $235.5 million in the prior-year quarter.

The company made no share repurchases during the quarter. On Oct. 20, its board approved a new $1 billion share repurchase authorization extending through December 2028, replacing the previous program.

MEDP Raises 2026 Earnings and Revenue Outlook

For full-year 2026, Medpace now expects revenues of $2.835-$2.855 billion, compared with its previous projection of $2.805-$2.885 billion. The revised range indicates year-over-year growth of 12-12.8%.

The company raised its EBITDA outlook to $638-$652 million from $618-$642 million. Net income is now projected at $514-$524 million, up from the previous $494-$514 million range. Earnings per share guidance increased to $17.97-$18.32 from $17.25-$17.95. The updated forecast assumes an effective tax rate of 19-19.5% and excludes additional share repurchases.

How Have Estimates Been Moving Since Then?

It turns out, fresh estimates have trended upward during the past month.

VGM Scores

At this time, Medpace has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Medpace has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Published in